> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novocure Raises 2026 Revenue Outlook To $736 Million-$743 Million After Record Quarter
- URL: https://www.bullished.co/novocure-raises-2026-revenue-outlook-to-736-million-743-million-after-record-quarter-cbe8723b/
- Published: 2026-10-29T11:43:01.000Z
- Updated: 2026-10-29T11:43:01.000Z
- Description: The tumor-therapy maker also lifted its adjusted EBITDA outlook to $24 million to $34 million, from $0 million to $15 million.
- Author: Matteo Parrino
- Tags: SEC Filings, NVCR, Industry: Healthcare

[Novocure](https://www.bullished.co/tag/nvcr/), which makes wearable devices that deliver Tumor Treating Fields to fight cancer, raised its 2026 outlook on Thursday after [third-quarter revenue of $193.4 million](https://www.sec.gov/Archives/edgar/data/0001645113/000164511326000081/nvcr-20260930xpr.htm?ref=bullished.co), up 16% from a year earlier and a quarterly record, the company said. Full-year net revenue is now guided to $736 million to $743 million, up from $710 million to $725 million.

## Guidance up, loss narrower

Adjusted EBITDA, the company's earnings measure that strips out interest, taxes, depreciation, amortization and share-based pay, is now expected at [$24 million to $34 million](https://www.businesswire.com/news/home/20261029363518/en/Novocure-Reports-Third-Quarter-2026-Financial-Results-and-Raises-2026-Guidance?ref=bullished.co) for the year, versus the earlier $0 million to $15 million. For the quarter it was $15.7 million, against a negative $3.0 million a year ago.

The net loss narrowed to $10.4 million, or $0.09 per share, from $37.3 million, or $0.33 per share. Gross margin rose to 77% from 73%, which the company [attributed](https://www.businesswire.com/news/home/20261029363518/en/Novocure-Reports-Third-Quarter-2026-Financial-Results-and-Raises-2026-Guidance?ref=bullished.co) mainly to higher patient volumes and lower cost per active patient.

The outlook assumes mid-to-high single-digit revenue growth from Optune Gio, $30 million to $34 million combined from Optune Lua and Optune Pax, and quarterly gross margin in the mid-to-high 70s percent.

## Patients and products behind the quarter

Novocure ended September with 5,260 active patients worldwide, versus 4,416 a year earlier, a 19% rise. Optune Gio, its brain-cancer device and the biggest revenue source, had 4,729 active patients, up 11%.

The U.S. brought in $111.9 million of revenue, Germany $24.9 million, France $18.7 million and Japan $14.5 million. Other markets added $18.8 million, and $4.4 million came from one-time benefits tied to higher claims approval rates in the U.S. and Germany.

Optune Lua, for lung cancer, and Optune Pax, for pancreatic cancer, together brought in $11.9 million, with $8.2 million from Lua and $3.7 million from Pax. Lua had 255 active patients, up 83%, and Pax had 276\. Greater China revenue from the Zai Lab partnership was $4.5 million.

CEO Frank Leonard said the company is "well-positioned to achieve the commercial, clinical and financial goals we set out in January."

## Cash, costs and the fourth-quarter calendar

Cash and short-term investments totaled $463.5 million at September 30\. Research and clinical spending rose 8% to $58.1 million, mostly on the KEYNOTE D58 trial, while sales and marketing fell 9% to $53.3 million and general and administrative costs fell 5% to $43.6 million.

In October, Japan's health ministry approved Optune Pax for locally advanced pancreatic cancer, and Novocure signed a trial collaboration with Verastem Oncology to test TTFields with chemotherapy and Verastem's investigational KRAS G12D inhibitor VS-7375 in that disease.

Two fourth-quarter milestones are on the company's calendar: an FDA decision on TTFields for brain metastases from non-small cell lung cancer, and completed enrollment in the KEYNOTE D58 glioblastoma trial.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — NovoCure Ltd (NVCR)](https://www.sec.gov/Archives/edgar/data/0001645113/000164511326000081/nvcr-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit nvcr-20260930xpr.htm — NovoCure Ltd 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001645113/000164511326000081/nvcr-20260930xpr.htm?ref=bullished.co) — SEC EDGAR
- [Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance](https://www.businesswire.com/news/home/20261029363518/en/Novocure-Reports-Third-Quarter-2026-Financial-Results-and-Raises-2026-Guidance?ref=bullished.co) — businesswire.com

### More on Novocure

- [Novocure Turns Cash-Flow Positive For Nine Months, With $22.8 Million From Unpaid Bills And A $25 Million Debt Slice Now Due](https://www.bullished.co/novocure-turns-cash-flow-positive-for-nine-months-with-22-8-million-from-unpaid-bills-and-5369ced4/)

[All Novocure (NVCR) coverage →](https://www.bullished.co/tag/nvcr/)